Health Condition 1: D33- Benign neoplasm of brain and otherparts of central nervous system Health Condition 2: D32- Benign neoplasm of meninges Health Condition 3: D09- Carcinoma in situ of other and unspecified sites Health Condition 4: F33- Major depressive disorder, recurrent Health Condition 5: F32- Major depressive disorder, singleepisode Health Condition 6: C71- Malignant neoplasm of brain Health Condition 7: C700- Malignant neoplasm of cerebral meninges Health Condition 8: C709- Malignant
Conditions
Interventions
Intervention1: Phase 1: Pilot testing of Group intervention for adjustment to primary brain tumour: Qual 1: Qualitative interviews with 16 patients individually, 3 Focus Group Discussions (FGDs) with
ii. Helplessness, hopelessness and anxious preoccupations
iii. Finding emotional support
iv. Developing resilience and reviving fighting spirit
v. Dealing with uncertainty
vi. Seeking professional help. Total duration of the pilot would be 4 months from the date of CTRI registration.
Intervention2: Phase 1:Quan 1: Pilot testing of intervention for 12 patients with pre-t
ii. Helplessness, hopelessness and anxiouspreoccupations
iv. Developingresilience and reviving fighting spirit
vi.Seeking professional help.
Intervention3: Phase 2:Follow-up: Assessments with 75 patients at 1st and 3rd month from the date of surgery.
Intervention4: Phase 2: Group intervention for adjustment to
Sponsors
Hubert Dan V
Eligibility
Inclusion criteria
Inclusion criteria: Patients who can follow English, Hindi, Tamil, Kannada.
Exclusion criteria
Exclusion criteria: FOR PATIENTS - i) Patients diagnosed with metastatic brain tumour as per histopathological report. ii) Patients with history of neuro-developmental disorders leading to mental retardation. iii) Patients with organic mental illness, i.e. phenomena known to occur as a direct consequence of malignant entity’s interaction with brain in form of growth of tumour; i.e., screening tool HMSE score below 19. iv) Patients experiencing cognitive impairment as a consequence/sequela of pharmacological or neurosurgical interventions for disorders; i.e., screening tool HMSE score below 19. FOR EXPERTS - i) Non-academicians, i.e., those working professionals below the cadre of lecturer/assistant professor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adjustment to illness (as assessed by Mini-MAC score)Timepoint: 1. Baseline i.e. at pre-surgery stage, before the first group intervention session. 2. One week from the baseline, i.e. after the last group intervention session. 3. Follow-up after four weeks from the date of surgery. 4. Follow-up after twelve weeks from the date of surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life (health related, asassessed by CDC HrQOL-14 score)Timepoint: 1. Baseline i.e. at pre-surgery stage, before the first group intervention session. 2. One week from the baseline, i.e. after the last group intervention session. 3. Follow-up after four weeks from the date of surgery. 4. Follow-up after twelve weeks from the date of surgery.;Symptom burden (of psychological issues, as assessed by DASS-21 score)Timepoint: 1. Baseline i.e. at pre-surgery stage, before the first group intervention session. 2. One week from the baseline, i.e. after the last group intervention session. 3. Follow-up after four weeks from the date of surgery. 4. Follow-up after twelve weeks from the date of surgery. | — |
Countries
India
Contacts
Public ContactDr L Ponnuchamy
National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru
Outcome results
None listed